SLE Disease Activity Index Glucocorticosteroid Index (SLEDAI-2KG) Identifies More Responders Than Sledai-2K

被引：0
|
作者：
Touma, Zahi [1 ]
Gladman, Dafna D. [2 ]
Su, Jiandong [3 ]
Anderson, Nicole [2 ]
Urowitz, Murray [2 ]
机构：
[1] Univ Toronto, Inst Hlth Policy Management & Evaluat, Div Rheumatol, Rheumatol, Toronto, ON, Canada
[2] Univ Toronto, Toronto Western Hosp, Rheumatol, Toronto, ON, Canada
[3] Univ Toronto, Toronto Western Hosp, Toronto, ON, Canada
来源：
ARTHRITIS & RHEUMATOLOGY | 2017年 / 69卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1624
引用
收藏
页数：3
相关论文
共 50 条
  • [31] PERFORMANCE OF SLEDAI-2K RESPONDER INDEX-50 IN A RANDOMIZED PLACEBO-CONTROLLED TRIAL WITH USTEKINUMAB (UST) IN SYSTEMIC LUPUS ERYTHEMATOSUS
    Touma, Zahi
    Gladman, Dafna
    Fei, Kaiyin
    Gregan, Irene
    Zazzetti, Federico
    Gordon, Robert
    Lo, Kim Hung
    Rose, Shawn
    Urowitz, Murray
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2019, 25 : S39 - S39
  • [32] Development and Assessment of User Satisfaction of the Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) Responder Index-50 (SRI-50) Website with Computer-Adaptive Training and Examination Modules
    Touma, Zahi
    Gladman, Dafna
    Mackinnon, Anne
    Carette, Simon
    Abu-Shakra, Mahmoud
    Askanase, Anca
    Nived, Ola
    Hanly, John
    Landolt-Marticorena, Carolina
    Tam, Lai-Shan
    Toloza, Sergio
    Nikpour, Mandana
    Riddell, Claire
    Steiman, Amanda
    Eder, Lihi
    Haddad, Amir
    Barber, Claire
    Urowitz, Murray B.
    [J]. JOURNAL OF RHEUMATOLOGY, 2012, 39 (08) : 1711 - 1711
  • [33] BILAG-2004 index captures systemic lupus erythematosus disease activity better than SLEDAI-2000
    Yee, C-S
    Isenberg, D. A.
    Prabu, A.
    Sokoll, K.
    Teh, L-S
    Rahman, A.
    Bruce, I. N.
    Griffiths, B.
    Akil, M.
    McHugh, N.
    D'Cruz, D.
    Khamashta, M. A.
    Maddison, P.
    Zoma, A.
    Gordon, C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (06) : 873 - 876
  • [34] RESPONSIVENESS AND TEST-RETEST RELIABILITY OF NEW DISEASE ASSESSMENT INSTRUMENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN RELATION TO SLEDAI-2K
    Chatham, W. W.
    Collins, C. E.
    Gaylis, N.
    Busch, H.
    Hautamaki, E.
    Narayanan, S.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2016, 75 : 657 - 658
  • [35] SLE-DAS AS AN ALTERNATIVE TOOL TO MEASURE ACTIVITY OF SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON WITH SLEDAI-2K, IN A POPULATION FROM THE DOMINICAN REPUBLIC. PILOT STUDY
    Perez Rodriguez, L.
    Alvarez Santana, R. A.
    Garcia, D.
    Polanco Mora, T.
    Concepcion Sanchez, L.
    Paulino, I.
    Mercedes, I.
    Rodriguez Bautista, E.
    Valdez, T.
    Feriz, A.
    Munoz Louis, R.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 814 - 814
  • [36] Implementation of Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) Documentation in Systemic Lupus Erythematosus (SLE) Patients at an Academic Medical Center
    Chung, Sarah H.
    Juo, Hsin-Hsuan
    Thomason, Jenna
    Bays, Alison
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [37] The Effect of Anifrolumab on Cutaneous Manifestations and Arthritis in Moderate to Severe Systemic Lupus Erythematosus (SLE) Using Categorical SLEDAI-2K Responses and Continuous Measures of Activity As Outcome Measures
    Merrill, J. T.
    Furie, R.
    Werth, Victoria P.
    Khamashta, M.
    Drappa, J.
    Wang, L.
    Illei, G.
    [J]. ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [38] Circulating levels of iC3b and C3 levels correlate with SLEDAI-2K Responder Index-50 (S2K RI-50) disease activity scores the CASTLE (Complement Activation Signatures in Systemic Lupus Erythematosus (SLE)) study
    Kim, A. H. J.
    Strand, V.
    Mathis, N.
    Fairweather, W. R.
    Sen, D. P.
    Sinclair, K. C.
    Miner, J. M.
    Schramm, E. C.
    Bruchas, R. R.
    Staten, N.
    Stiening, C. M.
    Atkinson, J. P.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2015, 33 (03) : S42 - S42
  • [39] SLEDAI-2K AND POLYARTHRITIS ARE THE BEST PREDICTORS OF RESPONSE TO BELIMUMAB IN PATIENTS WITH ACTIVE SLE IN CLINICAL PRACTICE SETTING: DATA FROM MULTI CENTRIC ITALIAN STUDY
    Bettio, S.
    Iaccarino, L.
    Reggia, R.
    Emmi, G.
    Ceccarelli, F.
    Ubiali, T.
    Bortoluzzi, A.
    De Marchi, G.
    Bocci, E. Bartoloni
    Andreoli, L.
    Zen, M.
    Emmi, L.
    Conti, F.
    Gerosa, M.
    Meroni, P. L.
    Govoni, M.
    De Vita, S.
    Gerli, R.
    Tincani, A.
    Doria, A.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2016, 34 (04) : S12 - S12
  • [40] SLEDAI-2K Responder Index-50 Is Effective in Demonstrating Partial Response in a Phase 2, Randomized Placebo-Controlled Study of Ustekinumab in Patients with Active Systemic Lupus Erythematosus
    Touma, Zahi
    Urowitz, Murray
    Gladman, Dafna D.
    Wagner, Carrie
    Zhou, Bei
    Gordon, Robert
    Hsu, Benjamin
    Chevrier, Marc
    Rose, Shawn
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
12345